Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual ... Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.11 | -2.82776349614 | 3.89 | 4 | 3.6 | 7449 | 3.74932976 | CS |
4 | -0.465 | -10.9540636042 | 4.245 | 4.33 | 3.6 | 6387 | 3.81473752 | CS |
12 | -0.34 | -8.25242718447 | 4.12 | 5.2 | 2.78 | 13859 | 3.77104522 | CS |
26 | -0.16 | -4.06091370558 | 3.94 | 5.2 | 2.78 | 9162 | 3.87201458 | CS |
52 | -1.99 | -34.4887348354 | 5.77 | 5.93 | 2.78 | 6962 | 3.85686713 | CS |
156 | -18.92 | -83.3480176211 | 22.7 | 23.7 | 2.40101 | 85542 | 12.35108912 | CS |
260 | -10.62 | -73.75 | 14.4 | 58.5 | 2.40101 | 865358 | 27.31964209 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.